Copyright Reports & Markets. All rights reserved.

Global Mantle Cell Lymphoma Treatment Market Insights, Forecast to 2025

Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Mantle Cell Lymphoma Treatment Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Mantle Cell Lymphoma Treatment Market Size Growth Rate by Product
      • 1.4.2 Acalabrutinib
      • 1.4.3 JCAR-017
      • 1.4.4 JNJ-64052781
      • 1.4.5 Acalisib
      • 1.4.6 IGN-002
      • 1.4.7 IMGN-529
      • 1.4.8 AFM-11
      • 1.4.9 Others
    • 1.5 Market by End User
      • 1.5.1 Global Mantle Cell Lymphoma Treatment Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Mantle Cell Lymphoma Treatment Market Size
      • 2.1.1 Global Mantle Cell Lymphoma Treatment Revenue 2014-2025
      • 2.1.2 Global Mantle Cell Lymphoma Treatment Sales 2014-2025
    • 2.2 Mantle Cell Lymphoma Treatment Growth Rate by Regions
      • 2.2.1 Global Mantle Cell Lymphoma Treatment Sales by Regions
      • 2.2.2 Global Mantle Cell Lymphoma Treatment Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Mantle Cell Lymphoma Treatment Sales by Manufacturers
      • 3.1.1 Mantle Cell Lymphoma Treatment Sales by Manufacturers
      • 3.1.2 Mantle Cell Lymphoma Treatment Sales Market Share by Manufacturers
      • 3.1.3 Global Mantle Cell Lymphoma Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Mantle Cell Lymphoma Treatment Revenue by Manufacturers
      • 3.2.1 Mantle Cell Lymphoma Treatment Revenue by Manufacturers (2014-2019)
      • 3.2.2 Mantle Cell Lymphoma Treatment Revenue Share by Manufacturers (2014-2019)
    • 3.3 Mantle Cell Lymphoma Treatment Price by Manufacturers
    • 3.4 Mantle Cell Lymphoma Treatment Manufacturing Base Distribution, Product Types
      • 3.4.1 Mantle Cell Lymphoma Treatment Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Mantle Cell Lymphoma Treatment Product Type
      • 3.4.3 Date of International Manufacturers Enter into Mantle Cell Lymphoma Treatment Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Mantle Cell Lymphoma Treatment Sales by Product
    • 4.2 Global Mantle Cell Lymphoma Treatment Revenue by Product
    • 4.3 Mantle Cell Lymphoma Treatment Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Mantle Cell Lymphoma Treatment Breakdown Data by End User

    6 North America

    • 6.1 North America Mantle Cell Lymphoma Treatment by Countries
      • 6.1.1 North America Mantle Cell Lymphoma Treatment Sales by Countries
      • 6.1.2 North America Mantle Cell Lymphoma Treatment Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Mantle Cell Lymphoma Treatment by Product
    • 6.3 North America Mantle Cell Lymphoma Treatment by End User

    7 Europe

    • 7.1 Europe Mantle Cell Lymphoma Treatment by Countries
      • 7.1.1 Europe Mantle Cell Lymphoma Treatment Sales by Countries
      • 7.1.2 Europe Mantle Cell Lymphoma Treatment Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Mantle Cell Lymphoma Treatment by Product
    • 7.3 Europe Mantle Cell Lymphoma Treatment by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Mantle Cell Lymphoma Treatment by Countries
      • 8.1.1 Asia Pacific Mantle Cell Lymphoma Treatment Sales by Countries
      • 8.1.2 Asia Pacific Mantle Cell Lymphoma Treatment Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Mantle Cell Lymphoma Treatment by Product
    • 8.3 Asia Pacific Mantle Cell Lymphoma Treatment by End User

    9 Central & South America

    • 9.1 Central & South America Mantle Cell Lymphoma Treatment by Countries
      • 9.1.1 Central & South America Mantle Cell Lymphoma Treatment Sales by Countries
      • 9.1.2 Central & South America Mantle Cell Lymphoma Treatment Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Mantle Cell Lymphoma Treatment by Product
    • 9.3 Central & South America Mantle Cell Lymphoma Treatment by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Mantle Cell Lymphoma Treatment by Countries
      • 10.1.1 Middle East and Africa Mantle Cell Lymphoma Treatment Sales by Countries
      • 10.1.2 Middle East and Africa Mantle Cell Lymphoma Treatment Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Mantle Cell Lymphoma Treatment by Product
    • 10.3 Middle East and Africa Mantle Cell Lymphoma Treatment by End User

    11 Company Profiles

    • 11.1 Astex Pharmaceuticals, Inc.
      • 11.1.1 Astex Pharmaceuticals, Inc. Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Astex Pharmaceuticals, Inc. Mantle Cell Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Astex Pharmaceuticals, Inc. Mantle Cell Lymphoma Treatment Products Offered
      • 11.1.5 Astex Pharmaceuticals, Inc. Recent Development
    • 11.2 Bayer AG
      • 11.2.1 Bayer AG Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Bayer AG Mantle Cell Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Bayer AG Mantle Cell Lymphoma Treatment Products Offered
      • 11.2.5 Bayer AG Recent Development
    • 11.3 Bristol-Myers Squibb Company
      • 11.3.1 Bristol-Myers Squibb Company Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Bristol-Myers Squibb Company Mantle Cell Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Bristol-Myers Squibb Company Mantle Cell Lymphoma Treatment Products Offered
      • 11.3.5 Bristol-Myers Squibb Company Recent Development
    • 11.4 Celgene Corporation
      • 11.4.1 Celgene Corporation Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Celgene Corporation Mantle Cell Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Celgene Corporation Mantle Cell Lymphoma Treatment Products Offered
      • 11.4.5 Celgene Corporation Recent Development
    • 11.5 Cellular Biomedicine Group, Inc.
      • 11.5.1 Cellular Biomedicine Group, Inc. Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Cellular Biomedicine Group, Inc. Mantle Cell Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Cellular Biomedicine Group, Inc. Mantle Cell Lymphoma Treatment Products Offered
      • 11.5.5 Cellular Biomedicine Group, Inc. Recent Development
    • 11.6 Eisai
      • 11.6.1 Eisai Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Eisai Mantle Cell Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Eisai Mantle Cell Lymphoma Treatment Products Offered
      • 11.6.5 Eisai Recent Development
    • 11.7 EpiZyme, Inc.
      • 11.7.1 EpiZyme, Inc. Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 EpiZyme, Inc. Mantle Cell Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 EpiZyme, Inc. Mantle Cell Lymphoma Treatment Products Offered
      • 11.7.5 EpiZyme, Inc. Recent Development
    • 11.8 Fate Therapeutics, Inc.
      • 11.8.1 Fate Therapeutics, Inc. Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Fate Therapeutics, Inc. Mantle Cell Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Fate Therapeutics, Inc. Mantle Cell Lymphoma Treatment Products Offered
      • 11.8.5 Fate Therapeutics, Inc. Recent Development
    • 11.9 Genentech, Inc.
      • 11.9.1 Genentech, Inc. Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Genentech, Inc. Mantle Cell Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Genentech, Inc. Mantle Cell Lymphoma Treatment Products Offered
      • 11.9.5 Genentech, Inc. Recent Development
    • 11.10 Gilead Sciences, Inc.
      • 11.10.1 Gilead Sciences, Inc. Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Gilead Sciences, Inc. Mantle Cell Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Gilead Sciences, Inc. Mantle Cell Lymphoma Treatment Products Offered
      • 11.10.5 Gilead Sciences, Inc. Recent Development
    • 11.11 GlaxoSmithKline Plc
    • 11.12 Hutchison MediPharma Limited
    • 11.13 ImmunoGen, Inc.
    • 11.14 Immunomedics, Inc.

    12 Future Forecast

    • 12.1 Mantle Cell Lymphoma Treatment Market Forecast by Regions
      • 12.1.1 Global Mantle Cell Lymphoma Treatment Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Mantle Cell Lymphoma Treatment Revenue Forecast by Regions 2019-2025
    • 12.2 Mantle Cell Lymphoma Treatment Market Forecast by Product
      • 12.2.1 Global Mantle Cell Lymphoma Treatment Sales Forecast by Product 2019-2025
      • 12.2.2 Global Mantle Cell Lymphoma Treatment Revenue Forecast by Product 2019-2025
    • 12.3 Mantle Cell Lymphoma Treatment Market Forecast by End User
    • 12.4 North America Mantle Cell Lymphoma Treatment Forecast
    • 12.5 Europe Mantle Cell Lymphoma Treatment Forecast
    • 12.6 Asia Pacific Mantle Cell Lymphoma Treatment Forecast
    • 12.7 Central & South America Mantle Cell Lymphoma Treatment Forecast
    • 12.8 Middle East and Africa Mantle Cell Lymphoma Treatment Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Mantle Cell Lymphoma Treatment Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Mantle Cell Lymphoma Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Mantle Cell Lymphoma Treatment market based on company, product type, end user and key regions.

      This report studies the global market size of Mantle Cell Lymphoma Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Mantle Cell Lymphoma Treatment in these regions.
      This research report categorizes the global Mantle Cell Lymphoma Treatment market by top players/brands, region, type and end user. This report also studies the global Mantle Cell Lymphoma Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Astex Pharmaceuticals, Inc.
      Bayer AG
      Bristol-Myers Squibb Company
      Celgene Corporation
      Cellular Biomedicine Group, Inc.
      Eisai
      EpiZyme, Inc.
      Fate Therapeutics, Inc.
      Genentech, Inc.
      Gilead Sciences, Inc.
      GlaxoSmithKline Plc
      Hutchison MediPharma Limited
      ImmunoGen, Inc.
      Immunomedics, Inc.

      Market size by Product
      Acalabrutinib
      JCAR-017
      JNJ-64052781
      Acalisib
      IGN-002
      IMGN-529
      AFM-11
      Others
      Market size by End User
      Hospital
      Clinic
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Mantle Cell Lymphoma Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Mantle Cell Lymphoma Treatment market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Mantle Cell Lymphoma Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Mantle Cell Lymphoma Treatment submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Mantle Cell Lymphoma Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Mantle Cell Lymphoma Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now